SCHEMBL2005489

SCHEMBL2005489

COC(=O)CNC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.48
LMNA P02545 3/20 0.46
HPGD P15428 2/20 0.46
ALOX12 P18054 1/20 0.46
GPR88 Q9GZN0 1/20 0.46
MAPT P10636 2/20 0.46
MITF O75030 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 2/20 0.45
ROCK2 O75116 1/20 0.45
ROCK1 Q13464 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
OPRK1 P41145 1/20 0.44
UTS2R Q9UKP6 1/20 0.44
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949920 0.80 PKM (0.50) PKMLMNAHPGDGPR88CD274
SCHEMBL13136011 0.74 GPR88 (0.54) LMNAGPR88MAPTMITFHTT
SCHEMBL13626320 0.74 GPR88 (0.54) LMNAGPR88MAPTMITFHTT
SCHEMBL4148021 0.73 GPR88 (0.53) LMNAGPR88MAPTMITFHTT
SCHEMBL22229267 0.73 GPR88 (0.53) LMNAGPR88MAPTMITFHTT
SCHEMBL8305667 0.73 OPRK1 (0.53) CYP2D6OPRK1
SCHEMBL1222340 0.73 MAPT (0.49) HPGDMAPTSMN1; SMN2ALDH1A1
SCHEMBL11489064 0.73 ALDH1A1 (0.56) PKMLMNANPC1ALDH1A1
SCHEMBL2949858 0.71 CYP3A4 (0.51) PKMLMNASMN1; SMN2ALDH1A1ROCK2
SCHEMBL1239640 0.71 POLB (0.50) LMNAGPR88MAPTMITFHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 PKM 3656/4885LMNA 4840/4885HPGD 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.